Finance

Lists
Q3 2026 earnings • released • EPS beat +19,31% • Revenue beat +3,96%
See results
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
R$117,00
0,00%
(0,00) 1D
3 Nov., 11:50:35 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for T1EV34...
Mkt. cap
155,55 mjd
Avg. vol.
32,00
Volume
0,00
52-wk high
R$106,80
52-wk low
R$60,39
Shares outstanding
1,17 mjd
No. of employees
32 k
Mkt. cap
155,55 mjd
Avg. vol.
32,00
Volume
0,00
52-wk high
R$106,80
52-wk low
R$60,39
Shares outstanding
1,17 mjd
No. of employees
32 k
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Bdr
CEORichard Francis
Employees32 k
Founded13 Feb. 1944
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteteva.co.il
Last report
03 Nov. 2026
Fiscal period
Q3 2026
USD 0,86 / USD 0,72
+19,31%beat
Revenue / Est. (USD)
4,40 mjd / 4,23 mjd
+3,96%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
4,48 mjd
4,71 mjd
3,98 mjd
4,14 mjd
Cost of goods sold
2,18 mjd
2,06 mjd
2,01 mjd
1,99 mjd
Cost of revenue
2,18 mjd
2,06 mjd
2,01 mjd
1,99 mjd
Research and development expenses
256,00 m
267,00 m
222,00 m
970,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 m
1,12 mjd
1,00 mjd
1,03 mjd
Operating expense
1,24 mjd
1,37 mjd
1,21 mjd
1,99 mjd
Total operating expenses
3,41 mjd
3,43 mjd
3,22 mjd
3,98 mjd
Operating income
1,07 mjd
1,28 mjd
763,00 m
167,00 m
Other non operating income
-27,00 m
-
-13,00 m
-69,00 m
EBT including unusual items
648,00 m
90,00 m
436,00 m
-455,00 m
EBT excluding unusual items
832,00 m
1,08 mjd
547,00 m
-57,00 m
Income tax expense
214,00 m
-390,00 m
67,00 m
121,00 m
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 m
-17,00 m
-14,00 m
-18,00 m
Net income
433,00 m
480,00 m
369,00 m
-576,00 m
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 m
-
-
Interest expense
-205,00 m
-280,00 m
-191,00 m
-186,00 m
Net interest expenses
-205,00 m
-188,00 m
-191,00 m
-186,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 mjd
1,54 mjd
1,00 mjd
408,00 m
Gain or loss from assets sale
-
-
-8,00 m
-12,00 m
Upcoming events
AI content may include mistakes. Learn more
Google-programme